drugset / Trial / NCT00230542
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
Phase 2
Completed
44 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabMassachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-07
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |